We are live on ! Find out more
TPST icon

Tempest Therapeutics
TPST

80 hedge funds and large institutions have $206M invested in Tempest Therapeutics in 2016 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 17 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $149M → $206M (+$56.9M)

35% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 17

6% less funds holding

Funds holding: 85 → 80 (-5)

35% less call options, than puts

Call options by funds: $160K | Put options by funds: $247K

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

Holders
80
Holders Change
-5
Holders Change %
-5.88%
% of All Funds
2.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
23
Reduced
17
Closed
14
Calls
$160K
Puts
$247K
Net Calls
-$87K
Net Calls Change
+$121K

Top Buyers

Rank Fund Capital Flow
1
PCM
Portolan Capital Management
Massachusetts
+$2.86M
2
Northern Trust
Northern Trust
Illinois
+$1.79M
3
Deutsche Bank
Deutsche Bank
Germany
+$1.18M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$778K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$633K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$2.3M
2
Marshall Wace
Marshall Wace
United Kingdom
-$1.47M
3
Invesco
Invesco
Georgia
-$961K
4
Jennison Associates
Jennison Associates
New York
-$760K
5
Millennium Management
Millennium Management
New York
-$712K
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Credit Suisse
Switzerland
$185K – – –
ProShare Advisors
52
ProShare Advisors
Maryland
$182K -$18.1K -1 -10%
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$176K -$54.3K -3 -27%
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$166K – – –
Dimensional Fund Advisors
55
Dimensional Fund Advisors
Texas
$154K +$36.2K +2 +40%
CA
56
Commerzbank Aktiengesellschaft
Germany
$149K +$127K +7 New
Goldman Sachs
57
Goldman Sachs
New York
$145K +$54.3K +3 +75%
NFA
58
Nationwide Fund Advisors
Ohio
$144K – – –
AIG
59
American International Group
New York
$130K – – –
EMG
60
Ellington Management Group
Connecticut
$125K +$109K +6 New
BA
61
BlackRock Advisors
Delaware
$122K +$18.1K +1 +20%
NCMW
62
Northern Capital Management (Wisconsin)
Wisconsin
$106K -$90.5K -5 -50%
State Board of Administration of Florida Retirement System
63
State Board of Administration of Florida Retirement System
Florida
$86K – – –
QIM
64
Quantitative Investment Management
Virginia
$80K +$72.4K +4 New
Marshall Wace
65
Marshall Wace
United Kingdom
$79K -$1.47M -81 -95%
SG Americas Securities
66
SG Americas Securities
New York
$74K +$72.4K +4 New
AC
67
Amici Capital
New York
$72K – – –
SSA
68
Schonfeld Strategic Advisors
New York
$72K – – –
UBS Group
69
UBS Group
Switzerland
$71K +$18.1K +1 +50%
BG
70
BlackRock Group
United Kingdom
$62K -$90.5K -5 -63%
BlackRock
71
BlackRock
New York
$46K – – –
MLM
72
Mount Lucas Management
Pennsylvania
$34K +$18.1K +1 +100%
Legal & General Group
73
Legal & General Group
United Kingdom
$32K – – –
Canada Life
74
Canada Life
Manitoba, Canada
$25K – – –
CLOS
75
Compagnie Lombard Odier SCmA
Switzerland
$24K – – –
1 2
3
4 5

TPST Hedge Fund Activity: Q3 2016 in Review

80 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2016, worth a combined $206M — up 38% from $149M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of TPST and 9 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 23 added.

The largest buyer was Portolan Capital Management, adding an estimated $2.86M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.3M sold.

  • 80 institutional investors held Tempest Therapeutics (TPST) as of Q3 2016, down from 85 in Q2 2016.
  • Funds reported $206M of Tempest Therapeutics stock for Q3 2016, up 38% quarter-over-quarter.
  • 9 funds opened new Tempest Therapeutics positions in Q3 2016 and 14 closed out, a net change of -5 holders.
  • The largest Tempest Therapeutics buyer in Q3 2016 was Portolan Capital Management, an estimated $2.86M added.
  • The largest Tempest Therapeutics seller in Q3 2016 was JP Morgan Chase, an estimated $2.3M sold.

Based on aggregated 13F filings for Q3 2016.